Polydeoxyribonucleotide, as a Novel Approach for the Management of Medication-Related Osteonecrosis of the Jaw: A Preliminary Observational Study
Journal of Korean Dental Science
;
: 57-61, 2018.
Artigo
em Inglês
| WPRIM
| ID: wpr-764786
ABSTRACT
PURPOSE:
Polydeoxyribonucleotide (PDRN), consisting of a mixture of deoxyribonucleotide polymers, has been suggested to have anti-inflammatory effects and enhance angiogenesis as an adenosine A(2A) receptor agonist. The aim of this study was to report the effectiveness of PDRN as an adjuvant therapy after surgical debridement in MRONJ (medication-related osteonecrosis of the jaw) patients. MATERIALS ANDMETHODS:
Five patients (1 male, 4 females, age 65~79 years) who were diagnosed with MRONJ stage 2 or 3 underwent surgical debridement and PDRN mucosal injection. After surgical debridement, patients were subject to daily injection with 1 ml of PDRN around the surgical wound for 14 days.RESULT:
The patients' symptoms gradually disappeared. The surgical wound uneventfully healed, and no recurrence was observed during the follow-up period.CONCLUSION:
Although further studies are required, the present study first describes the possibility of PDRN as a useful option for MRONJ treatment.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Osteonecrose
/
Polímeros
/
Recidiva
/
Ferimentos e Lesões
/
Seguimentos
/
Desbridamento
/
Receptor A2A de Adenosina
/
Estudo Observacional
/
Arcada Osseodentária
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Journal of Korean Dental Science
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS